<DOC>
	<DOCNO>NCT00232011</DOCNO>
	<brief_summary>Pimecrolimus , ascomycin derivative , anti-inflammatory non-steroidal agent . In study , long-term safety efficacy pimecrolimus cream evaluate Japanese adult patient atopic dermatitis . This study 6-month extension study follow core study . THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES</brief_summary>
	<brief_title>Extension Study Assess Safety Efficacy Pimecrolimus Adult Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients complete core study whose participation study consider appropriate judged investigator Patients give write informed consent participation study Patients fail treatment compliance core study Patients major violation protocol core study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Atopic dermatitis , ASM981 , pimecrolimus</keyword>
</DOC>